$ALLO News

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Allogene: If MRD Holds, This Becomes A Completely Different Company

Allogene Therapeutics EVP And CFO Geoffrey Parker To Retire, Effective November 6

Allogene Therapeutics Announces Participation in September Investor Conference

Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?

Allogene (ALLO) Q2 2026 Earnings Call Transcript

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary

Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ...

Allogene Therapeutics Q2 Earnings Call Highlights

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics Files Prospectus For $500M Offering

Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma